{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=21", "query": { "intervention": "Combination 400", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1062, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T05:31:23.163Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00426296", "title": "SHARE: Simple HAART With Abacavir, Reyataz, and Epivir", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "Lipodystrophy" ], "interventions": [ { "name": "atazanavir (Reyataz)", "type": "DRUG" }, { "name": "ritonavir (Norvir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clinical Alliance for Research & Education - Infectious Diseases, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2006-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-11-01", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00426296" }, { "nct_id": "NCT00908024", "title": "Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Head and Neck Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "BMS-754807", "type": "DRUG" }, { "name": "cetuximab (Erbitux®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2009-10", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Durham, North Carolina • Madison, Wisconsin", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00908024" }, { "nct_id": "NCT02419560", "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Mantle-Cell", "Recurrent Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "ABT-199 and Ibrutinib Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Craig Portell, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2015-04", "completion_date": "2021-05", "has_results": false, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 4, "location_summary": "Duarte, California • Atlanta, Georgia • St Louis, Missouri + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419560" }, { "nct_id": "NCT01187446", "title": "Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cutaneous Lymphoma", "Cutaneous T-cell Lymphoma" ], "interventions": [ { "name": "Total skin electron beam therapy (TSEBT)", "type": "RADIATION" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 3, "location_summary": "Stanford, California • New Haven, Connecticut • Houston, Texas", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01187446" }, { "nct_id": "NCT00723658", "title": "S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "autologous-autologous tandem hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 29, "location_summary": "Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Beech Grove", "state": "Indiana" }, { "city": "Richmond", "state": "Indiana" }, { "city": "Lawrence", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00723658" }, { "nct_id": "NCT01488552", "title": "Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Immunohistochemistry (IHC) Analysis", "type": "GENETIC" }, { "name": "Metformin", "type": "DRUG" }, { "name": "mFOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "Pancreatic Cancer Research Team", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2011-11", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-08-18", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01488552" }, { "nct_id": "NCT02094443", "title": "Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "Liver Disease" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2014-03", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-10-13", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 11, "location_summary": "Bakersfield, California • Lancaster, California • San Diego, California + 6 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02094443" }, { "nct_id": "NCT03483038", "title": "A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 45, "start_date": "2018-12-13", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 4, "location_summary": "Gainesville, Florida • Orlando, Florida • Tallahassee, Florida + 1 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03483038" }, { "nct_id": "NCT00594984", "title": "Phase I/II Combination With Irinotecan- Erbitux", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (MCRC)" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Brivanib", "type": "DRUG" }, { "name": "Brivanib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2008-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 4, "location_summary": "Los Angeles, California • Louisville, Kentucky • St Louis, Missouri", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594984" }, { "nct_id": "NCT00874848", "title": "Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Imprime PGG Injection", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2009-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-11-03T05:31:23.163Z", "location_count": 5, "location_summary": "Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Dallas", "state": "Texas" }, { "city": "Midland", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874848" } ] }